search
Back to results

Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.

Primary Purpose

Diabetes type1

Status
Unknown status
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
Insulin glulisine
Insulin aspart
Insulin lispro
Sponsored by
Medical University of Warsaw
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes type1 focused on measuring diabetes type 1, insulin pump, prandial insulin requirement, pure protein meal, high protein meal, square bolus, square-wave bolus, insulin bolus, dietary protein

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • duration of type 1 diabetes longer than 12 months
  • insulin pump therapy longer than 3 months
  • written informed consent by patients and parents
  • insulin requirement more than 0,5 units/kg/day

Exclusion Criteria:

  • diabetes related complications (e.g. nephropathy)
  • chronic kidney diseases
  • any disease judged by the investigator to affect the trial
  • withdrawal of consent to participate in the study

Sites / Locations

  • Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

group A

group B

Arm Description

On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine

On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine

Outcomes

Primary Outcome Measures

Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Postprandial glycemia
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)

Secondary Outcome Measures

Hypoglycemia episodes
Hypoglycemia defined as a plasma glucose concentration below 65 mg/dl with or without symptoms
Glucose Area Under the Curve (AUC)
Measurements based on CGMS
Mean amplitude of glycemic excursion
measurements based on SMBG
The difference between the maximum and baseline glucose level
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)

Full Information

First Posted
February 12, 2016
Last Updated
July 28, 2016
Sponsor
Medical University of Warsaw
search

1. Study Identification

Unique Protocol Identification Number
NCT02685449
Brief Title
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
Official Title
Insulin Requirement for Pure- Protein Meal in Children With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion - a Cross-over, Randomized Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Unknown status
Study Start Date
February 2016 (undefined)
Primary Completion Date
February 2018 (Anticipated)
Study Completion Date
August 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a randomized, cross-over study. The aim of this study is to compare the post-prandial glycaemic variability after pure protein meal following with an administration of square-wave bolus of meal-insulin or without any meal-insulin bolus on the other day. Prolonged post-prandial glycaemic variability will be identified using the self-monitoring of blood glucose (10-point curve) and CGMS.
Detailed Description
The square-wave bolus (for meals rich in fat and/or protein) is evenly delivered over several hours as programmed by the patient. The required insulin dose will be calculated based on patient's insulin-exchange ratio. Pure protein meal will be given 3 hours after a first breakfast. To provide the minimal impact of the previous breakfast, all patients will receive up to 120 kcal of carbohydrates and <100 kcal from protein and fat for the first breakfast (without any extended bolus) Patients receive a standardized pure protein meal at a second breakfast time. Meal insulin will be given as a square bolus or no meal -insulin will be given at all. The 5h post-meal glucose excursions will be recorded by self-blood glucose measurements (SMBG) (every 30 minutes) and continuous glucose monitoring system (CGMS). The intervention is taking part under in-patient clinical conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes type1
Keywords
diabetes type 1, insulin pump, prandial insulin requirement, pure protein meal, high protein meal, square bolus, square-wave bolus, insulin bolus, dietary protein

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
group A
Arm Type
Placebo Comparator
Arm Description
On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine
Arm Title
group B
Arm Type
Active Comparator
Arm Description
On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal. The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial. Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine
Intervention Type
Drug
Intervention Name(s)
Insulin glulisine
Other Intervention Name(s)
Apidra®
Intervention Description
A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Intervention Type
Drug
Intervention Name(s)
Insulin aspart
Other Intervention Name(s)
NovoRapid®
Intervention Description
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Intervention Type
Drug
Intervention Name(s)
Insulin lispro
Other Intervention Name(s)
Humalog®
Intervention Description
A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Primary Outcome Measure Information:
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
30 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
60 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
90 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
120 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
150 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
180 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
210 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
240 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
270 minutes after the meal
Title
Postprandial glycemia
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
300 minutes after the meal
Secondary Outcome Measure Information:
Title
Hypoglycemia episodes
Description
Hypoglycemia defined as a plasma glucose concentration below 65 mg/dl with or without symptoms
Time Frame
5-hour study period
Title
Glucose Area Under the Curve (AUC)
Description
Measurements based on CGMS
Time Frame
5-hour study period
Title
Mean amplitude of glycemic excursion
Description
measurements based on SMBG
Time Frame
5-hour study period
Title
The difference between the maximum and baseline glucose level
Description
Post-prandial blood glucose excursions measured by self monitoring of blood glucose (SMBG)
Time Frame
5-hour study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: duration of type 1 diabetes longer than 12 months insulin pump therapy longer than 3 months written informed consent by patients and parents insulin requirement more than 0,5 units/kg/day Exclusion Criteria: diabetes related complications (e.g. nephropathy) chronic kidney diseases any disease judged by the investigator to affect the trial withdrawal of consent to participate in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kamila Indulska
Phone
48223179421
First Name & Middle Initial & Last Name or Official Title & Degree
Katarzyna Dżygało
Phone
48223179538
Email
k.dzygalo@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katarzyna Dżygało
Organizational Affiliation
Department of Pediatrics, Warsaw Medical University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kamila Indulska
Organizational Affiliation
University of Alberta
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Agnieszka Szypowska
Organizational Affiliation
University of Alberta
Official's Role
Study Chair
Facility Information:
Facility Name
Medical University
City
Warsaw
ZIP/Postal Code
02- 091
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Agnieszka Szypowska, MD, PhD
Phone
+48223179421
First Name & Middle Initial & Last Name & Degree
Kamila Indulska
First Name & Middle Initial & Last Name & Degree
Katarzyna Dżygało

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.

We'll reach out to this number within 24 hrs